Advanced Cancer Clinical Trials

50 studies are recruiting for advanced cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

   The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   I-Mab Site 1016, Goodyear, Arizona

   Locations

   6 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT07432295 on ClinicalTrials.gov

2. Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

   The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered outcomes, including financial worry, health-related quality of life (HRQoL…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Dignity Health, Phoenix, Arizona

   Locations

   7 in total

   Run by

   Alliance Foundation Trials, LLC.

   See if you can join NCT06963723 on ClinicalTrials.gov

3. ALIGN for Older Adults With Cancer in SNFs

   The goal of this clinical trial is to learn if it is possible to deliver a palliative care intervention called ALIGN (Assessing and Listening to Individual Goals and Needs) to hospitalized older adults with advanced cancer who are discharged to a skilled nursing facility and their caregivers. The m…

   Stage

   Not phased

   Ages

   18 to 98

   Site

   University of Colorado Anschutz Medical Campus, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT06616298 on ClinicalTrials.gov

4. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

   This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Cancer Center, Aurora, Colorado

   Locations

   5 in total

   Run by

   7 Hills Pharma, LLC

   See if you can join NCT06362369 on ClinicalTrials.gov

5. A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial

   To examine the feasibility and acceptability of chaplain-clinician led spiritual care (PEACE: Perception, Exploring, Addressing, Compassionate Connection, Embracing) intervention in patients with advanced cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07246954 on ClinicalTrials.gov

6. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

   Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Orlando, Florida

   Locations

   18 in total

   Run by

   Incyclix Bio

   See if you can join NCT05735080 on ClinicalTrials.gov

7. SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

   The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between do…

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Johns Hopkins University, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06389097 on ClinicalTrials.gov

8. Pilot Trial of Spiritual Care Interventions for Patients With Cancer

   This is a pilot trial of the effects of spiritual care interventions on spiritual well-being and readiness to engage in advance care planning (ACP) among black patients with advanced cancer recruited from outpatient settings to determine the feasibility of conducting a larger trial of effects of ea…

   Stage

   Not phased

   Ages

   18 and older

   Site

   New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

   Locations

   2 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT06811376 on ClinicalTrials.gov

9. Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services

   This study is testing whether electronic surveys can help patients with advanced cancer report their symptoms and care needs so their doctors can connect them to palliative/supportive care services sooner. The goal is to see if this approach can make it easier for patients to get support for sympto…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

   Run by

   Dartmouth-Hitchcock Medical Center

   See if you can join NCT07195513 on ClinicalTrials.gov

10. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

    This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stern Center for Cancer Clinical Trials and Research, Orange, California

    Locations

    21 in total

    Run by

    I-Mab Biopharma US Limited

    See if you can join NCT04900818 on ClinicalTrials.gov

11. Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

    The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions …

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Chicago Medicine, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05166694 on ClinicalTrials.gov

12. Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer

    To learn about the effects of an intervention program called Focused Acceptance and Commitment Therapy (FACT) on the level of anxiety patients diagnosed with cancer feel about death. To learn if an intervention program called Focused Acceptance and Commitment Therapy (FACT), designed to help reduce…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07105033 on ClinicalTrials.gov

13. Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)

    Many FDA-approved drugs are not available to patients with a particular cancer because there has been no successful clinical trial conducted for that drug against that cancer. In the absence of such a successful clinical trial, the drug is not included in the National Comprehensive Cancer Network (…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cancer Commons, Palo Alto, California

    Run by

    Cancer Commons

    See if you can join NCT07343024 on ClinicalTrials.gov

14. Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

    RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosph…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Honor Health Research Institute, Scottsdale, Arizona

    Locations

    14 in total

    Run by

    Riboscience, LLC.

    See if you can join NCT05270213 on ClinicalTrials.gov

15. Psilocybin Therapy in Advanced Cancer

    The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4…

    Stage

    Phase 2

    Ages

    21 to 100

    Site

    University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05398484 on ClinicalTrials.gov

16. A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

    The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebuli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    XCancer Research Network/Dothan Hematology & Oncology, Dothan, Alabama

    Locations

    14 in total

    Run by

    Krystal Biotech, Inc.

    See if you can join NCT06228326 on ClinicalTrials.gov

17. A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

    This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Miami Cancer Institute, Miami, Florida

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06174987 on ClinicalTrials.gov

18. Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

    Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    11 in total

    Run by

    Qurient Co., Ltd.

    See if you can join NCT05394103 on ClinicalTrials.gov

19. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    35 in total

    Run by

    Apollomics Inc.

    See if you can join NCT03175224 on ClinicalTrials.gov

20. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

    TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The s…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    D&H Cancer Research Center Llc, Margate, Florida

    Locations

    4 in total

    Run by

    Shanghai Allink Biotherapeutics Co., Ltd.

    See if you can join NCT06707610 on ClinicalTrials.gov

21. Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the un…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine, Irvine, California

    Locations

    4 in total

    Run by

    CJ Bioscience, Inc.

    See if you can join NCT05877430 on ClinicalTrials.gov

22. A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

    The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    Proviva Therapeutics, Inc.

    See if you can join NCT06190886 on ClinicalTrials.gov

23. A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

    This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Case Western Reserve University, Cleveland, Ohio

    Run by

    Biocity Biopharmaceutics Co., Ltd.

    See if you can join NCT06548672 on ClinicalTrials.gov

24. AIMS Cancer Outcomes Study

    The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect …

    Stage

    Not phased

    Ages

    Any age

    Site

    AIMS Institute, Seattle, Washington

    Run by

    Advanced Integrative Medical Science Institute

    See if you can join NCT04495790 on ClinicalTrials.gov

25. A Study in Patients With Advanced Cancers

    A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Austin, Austin, Texas

    Locations

    3 in total

    Run by

    BiOneCure Therapeutics Inc.

    See if you can join NCT05320588 on ClinicalTrials.gov